Structural Bioinformatics & HPC · UCAM
HPC-driven drug discovery, from molecule to clinic.
Twenty-five years building computational methods on supercomputers — delivering patented compounds, licensed assets and ongoing clinical studies. We partner with pharma, biotech, agri-food and academic groups worldwide.
What we do
Methods
We develop novel structural bioinformatics, AI and machine-learning methods for drug discovery, target characterisation and compound optimisation.
HPC
We implement them on supercomputers and on freely accessible web servers, enabling large-scale virtual screening and molecular dynamics campaigns.
Translation
Compounds discovered with our pipeline are patented, licensed and progressing into clinical studies — Murcia 2022 (colorectal cancer) and Murcia 2023 (weight-loss).
What we offer
Computational drug discovery
Structure-based virtual screening, molecular docking, molecular dynamics, pharmacophore modelling and consensus methods, applied to academic, biotech and pharma targets.
HPC capacity & SaaS access
Private HPC deployments, dedicated cluster scheduling and on-premise installations of our tools for partners who require scale, throughput or full data confidentiality.
AI on HPC
Custom interpretable machine-learning models (ADMET, QSAR, target prediction, image analysis and time-series forecasting) trained and deployed on supercomputing resources.
Imipramine → Fascin — colorectal cancer metastasis
Structure-based discovery of an FDA-approved antidepressant as a potent Fascin1 inhibitor that blocks invasion of colorectal tumour cells in vitro and in vivo. Patent licensed (2023). Clinical study started in Murcia (2022).
Explore our full pipeline →Group video presentation
Trusted by partners and collaborators
Partner with us
We are actively seeking biotech and pharmaceutical partners across three tracks:
Licensing
Patents available for licensing or sub-licensing across multiple targets and indications.
Co-development
Joint pre-clinical and clinical development of novel chemical entities with nanomolar activities.
Clinical-trial investment
Investment opportunities for ongoing clinical studies in colorectal cancer and weight-loss.
Contact: Prof. Horacio Pérez-Sánchez · hperez@ucam.edu